Updates are available Correction dated 2024-11-21

Article History

Received: 31 January 2024

Accepted: 21 August 2024

First Online: 24 October 2024

Change Date: 21 November 2024

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1186/s12885-024-13210-9

Declarations

:

: The study protocol and all amendments were reviewed by the Independent Ethics Committee or Institutional Review Board at each institution (for more information, please refer to the section in the Supplementary file). The study was conducted according to ICH E6 Guideline for Good Clinical Practice that has its origin in the Declaration of Helsinki. Informed consent was obtained from each patient before conducting any study-specific procedures including molecular pre-screening and screening as described in the protocol.

: Not applicable.

: AS had been on Advisory Board for BMS, Servier, Gilead, Pfizer, Eisai, BAYER, and MSD, and as consultant for Arqule, Sanofi, Incyte, and served as speaker’s Bureau for Takeda, BMS, Roche, Abbvie, Amgen, Celgene, Servier, Gilead, Astrazeneca, Pfizer, Arqule, Lilly, Sandoz, Eisai, Novartis, BAYER, MSD. GP had served as advisory board member for AbbVie, Amgen, AstraZeneca, Bayer, BMS, GlaxoSmithKline, Janssen, Eli Lilly, MSD, Novartis, Pfizer, Roche, Takeda, Sanofi, Daiichi Sankyo, and Sanofi. He has received financial support and speaker fees from AstraZeneca, Janssen, MSD, Novartis, Pfizer, Roche, Takeda, Blue Print, Apollomics, Amgen, Array Biopharma, IO Biotech. GP received other personal financial interests from Lung Cancer Medical Education TASC Committee from Janssen. In terms of non-financial interests, GP has held leadership roles as a council member for the Women for Oncology Committee Chair Fellowship and Award Committee, and Press Committee Faculty for lung and other thoracic tumors for ESMO. He has served as the President of the Spanish Federation of Medical Societies (FACME) from 2020 – 2022 and currently from 2023 – 2024. He is the former President of the Spanish Medical Oncology Society (SEOM), and a member and board member of the Scientific Committee of the Spanish Against Cancer Research Foundation (AECC), member of the IASLC Women in Thoracic Oncology Working Group. GP has advisory roles as a member of the Spanish National Health Advisory Board for the Spanish Minister of Health, advisory role for lung cancer screening evaluation for EUnetHTA, Spanish National Evaluation network (RedETS), and for EMA. DSWT received honoraria from Amgen, Bayer, Merck, Pfizer, Novartis, Boehringer, Ingelheim, Roche, Takeda. He has served as a consultant and advisory role for Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, DKSH, GlaxoSmithKline, Merck, Novartis, Pfizer, Roche and Takeda. He has received research grants from ACM Biolabs, Amgen, Astra Zeneca, Bayer and Pfizer outside this work. JZ reports personal fees from Sanofi, MSD, NanoString, Pfizer, and Novartis outside the submitted work; grants and personal fees from BMS, AstraZeneca, and Roche. AB has served as a consultant or on advisory boards for Amgen, AstraZeneca, Bristol Myers Squibb (BMS), Janssen, Merck, Novartis, Pfizer, Roche/Genentech, Sanofi, and Takeda. AB received fees for speaking and travels from Pfizer, Takeda, Roche, MERCK SHARP & DOHME (MSD). FB has no personal financial interests (since August 2021); Institutional financial interests from Abbvie, ACEA, Amgen, Astrazeneca, Bayer, BMS, Boehringer–Ingelheim, Eisai, Eli Lilly Oncology, F. Hoffmann–La Roche Ltd, Genentech, Ipsen, Ignyta, Innate Pharma, Loxo, Novartis, Medimmune, Merck, MSD, Pierre Fabre, Pfizer, Sanofi-Aventis and Takeda; Non-financial interests as Principal Investigator for Astra-Zeneca, BMS, Innate Pharma, Merck, Pierre Fabre and F. Hoffmann-La Roche, Ltd, sponsored trials (or ISR).TMK received consulting fees or honoraria for lectures from AstraZeneca, IMBDx, Inc., Janssen, Regeneron, Samsung Bioepis, Takeda, and Yuhan; had advisory role at AstraZeneca, Janssen, Regeneron, and Takeda; and received research grant from AstraZeneca-KHIDI outside this work. TRO received grants as an advisor or speaker from: AstraZeneca, Boehringer Ingelheim, Daiichi-Sankyo, Roche Pharma, Merck Sharp and Dohme, Novartis Pharma and Takeda Oncology, TRO received travel support from AstraZeneca and Janssen-Cilag.EF served on advisory boards for Abbvie, Amgen, Astra Zeneca, Bayer, Beigene, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, F. Hoffmann-La Roche, Gilead, Glaxo Smith Kline, Janssen, Merck Serono, Merck Sharp & Dohme, Novartis, Peptomyc, Pfizer, Regeneron, Sanofim Takeda, Turning Point, Daiichi Sankyo. EF has received speaker fees from Amgen, Astra Zeneca, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, F. Hoffmann- La Roche, Genentech, Janssen, Medical Trensa, Medscape, Merck Serono, Merck Sharp & Dohme, Peervoice, Pfizer, Sanofi, Takeda, and Touch Oncology. EF was a board member of Grifols. FAS and ESS do not have any competing interests to disclose. CC, ES, TM are employees of Novartis. TM holds shares with Novartis.